Lisata Therapeutics And Qilu Pharmaceutical Announce First Patient Treated In Qilu's Phase 2 Trial Of LSTA1 In Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Lisata Therapeutics And Qilu Pharmaceutical Announce First Patient Treated In Qilu's Phase 2 Trial Of LSTA1 In Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Lisata Therapeutics 和齊魯製藥宣佈在齊魯針對轉移性胰腺導管腺癌患者的 LSTA1 二期試驗中首次接受治療的患者
Lisata Therapeutics And Qilu Pharmaceutical Announce First Patient Treated In Qilu's Phase 2 Trial Of LSTA1 In Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Lisata Therapeutics 和齊魯製藥宣佈在齊魯針對轉移性胰腺導管腺癌患者的 LSTA1 二期試驗中首次接受治療的患者
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。